SGLT2 inhibitors have emerged as a new and very promising treatment option for the neutropenia‐/neutrophil dysfunction‐associated signs and symptoms in patients with GSD Ib. This evidence concerns the gene SLC5A2 and disorder of glycogen metabolism.